Overview

CD30 CAR-T in the Treatment of CD30 Positive Lymphoma

Status:
NOT_YET_RECRUITING

Trial end date:
2029-07-28

Target enrollment:

Participant gender:

Summary

The is a prospective, open-label, dose-climbing multicenter clinical study assessing the efficacy and safety of CD30 CAR-T in the treatment of r/r CD30+ lymphoma. Plan to recruit 15 subjects with r/r CD30+ lymphoma

Phase:

EARLY_PHASE1

Details

Lead Sponsor:

Shandong Qilu Cell Therapy Engineering Technology Co., Ltd

Collaborators:

First Affiliated Hospital of Guangxi Medical University
Shanxi Bethune Hospital
Tongji Hospital Affiliated to Tongji Medical College of HUST
Wuhan Central Hospital
Yichang Central People's Hospital